Core Insights - Oxford Nanopore Technologies achieved a 24% constant currency revenue growth for the year, surpassing its initial guidance of 20%-23% [3][7][4] - The company experienced significant growth across various product segments, particularly in clinical and biopharma markets, despite facing challenges such as NIH funding uncertainty and geopolitical issues in China [2][4][8] Revenue Growth - Clinical revenue grew over 60%, biopharma revenue increased by 30%, applied industrial revenue rose by 27%, and research revenue grew by 15% [2][7] - The Americas region showed strong momentum in the second half of the year, contributing to overall growth [3][7] Regional Performance - The Americas now derive more than half of their revenue from non-research segments, contrasting with EMEA where research remains a larger share [1] - In EMEA, academic growth exceeded 20% and clinical growth surpassed 50% [10] - Asia-Pacific faced challenges due to the roll-off of a significant contract and competitive pressures from local players, with China representing about 8% of total revenue [8][10] Product Dynamics - Higher-throughput devices like PromethION and P2i are becoming central for whole-genome and scale use cases, as customers increasingly skip earlier devices [5][11] - The MinION flow cell is suitable for small genomes and targeted sequencing, while the PromethION flow cell supports whole human genome sequencing [9][11] Financial Position - The company ended the year with GBP 302 million in cash, ahead of market expectations, and improved cash flow by shifting to a CapEx sales model [6][17][18] - Inventory optimization contributed to cash improvement, with over GBP 100 million in inventory at year-end [19] Cost Management and Future Targets - The company reduced headcount by 5% and is targeting EBITDA breakeven by 2027 and cash flow breakeven by 2028 [20][21] - Controlled operating expense growth and gross margin improvement are emphasized as key components to achieving these targets [21]

By end market, Sanghera said life science research tools remain the core of the business, representing 67% of revenue and growing 15% in 2025. He said applied markets now represent about one-third of revenue after increasing traction over the last two to three years, with clinical up 60% , biopharma up 30% , and applied industrial up 27% .He also pointed to the firm’s growth trajectory, stating that Oxford Nanopore has delivered 28% CAGR over the last five years and that growth in 2025 was supported by perf ...

OXFORD, England--(BUSINESS WIRE)-- #Nanopore--Oxford Nanopore Technologies today announces that the GridIONâ"¢ Dx is now both CE and UKCA marked, making it the company's first IVD device registered in the UK and Europe. The CE and UKCA certification confirms that GridIONâ"¢ Dx meets stringent international standards for quality, safety, and performance, positioning Oxford Nanopore for future adoption in regulated clinical markets and reflecting its long-term commitment to sequencing-based diagnostics. "Bein ...

Financial Data and Key Metrics Changes - Organic revenue declined 1% in Q1, primarily due to clinical stage timing from large customers in the cell therapy business and ongoing softness in biotech funding [4][19] - Adjusted EPS for the quarter was $0.42, flat year-over-year, while GAAP EPS increased to $0.24 from $0.21 in the prior year [18][19] - Total revenue for Q1 was $286.6 million, representing a 1% year-over-year decline on both an organic and reported basis [19] - Adjusted gross margin improved to 70.2%, up from 69.5% last year, driven by the exosome diagnostics divestiture and ongoing productivity initiatives [20] - Adjusted operating margin reached 29.9%, up 90 basis points year-over-year [20] Business Line Data and Key Metrics Changes - Protein sciences segment reported sales of $202.2 million, down 1% year-over-year, with organic revenue declining 3% [22] - Diagnostics and spatial biology segment sales were $79.5 million, down 4% year-over-year, but achieved 3% organic growth [22] - The protein analytical tools business showed notable strength from large pharma customers, contributing to organic growth [22] Market Data and Key Metrics Changes - Revenue from large pharma customers increased low double digits, while biotech spending continued to decline, resulting in high single-digit declines in Q1 [5][19] - North America experienced mid-single digit revenue decline, while Europe and Asia posted low single-digit growth [19][22] - China achieved its second consecutive quarter of growth, driven by strong performance in ProteinSimple analytical instruments and spatial biology portfolio [7][19] Company Strategy and Development Direction - The company is focused on productivity and cost management while investing in strategic growth pillars [5][17] - The acquisition of Wilson Wolf is expected to enhance the company's position in the cell therapy market, with plans to complete the acquisition by the end of calendar 2027 [9][10] - The company anticipates a return to positive organic growth in the second half of the fiscal year, driven by improving conditions in the biopharma sector and stabilization in U.S. academic markets [25][39] Management's Comments on Operating Environment and Future Outlook - Management noted that underlying market trends remain constructive, with early signs of stabilization in biotech activity levels [6][18] - The company expects Q2 organic growth to be consistent with Q1, reflecting continued strength in pharma and renewed growth in China [25] - Management expressed optimism about the recovery in biotech funding and the potential for lower interest rates to support investment levels in emerging biotech companies [6][35] Other Important Information - The company achieved an estimated 40% reduction in Scope 1 and 2 emissions during fiscal 2025, transitioning to 100% renewable electricity at its largest site [17] - The diagnostics business grew mid-single digits in Q1, supported by balanced performance across core diagnostic controls and kits [15] Q&A Session Summary Question: How long might the air pocket persist for GMP proteins? - Management indicated that the headwind from two large customers would be approximately 400 basis points in Q2, but they remain positive about the underlying recovery in the biotech markets [28][30] Question: Are growth plans for fiscal 2026 still low single-digit? - Management confirmed that plans remain unchanged, with a commitment to the cell therapy market and expectations for low single-digit growth for the year [30] Question: What is the outlook for the second half of the fiscal year? - Management expects a return to positive organic growth in the second half, driven by easing headwinds and improved market conditions [25][39] Question: Can you provide an update on Wilson Wolf? - Wilson Wolf had a flat quarter, but management remains optimistic about its potential to accelerate growth in the cell therapy market [43][44] Question: What are the assumptions for government shutdown impacts? - Management noted no significant changes in academic customer buying patterns due to the government shutdown, indicating stability in the academic market [52]

Core Insights - Oxford Nanopore Technologies will present its advancements in human genetics at the ASHG 2025 industry session, focusing on integrated analysis for better disease insights [1] Group 1: Company Developments - The presentation will showcase the unique capabilities of the PromethION platform in delivering comprehensive whole genomes and methylomes [1]

Core Viewpoint - The article highlights the significant role of UK universities in fostering entrepreneurship through the establishment of spinout companies, with a focus on various metrics such as company formation, funding events, and success rates, indicating a thriving ecosystem for innovation and commercialization of research [3][79]. Group 1: Company Formation - A total of 2064 spinout companies have been established by professors in UK universities, with 1337 still operational, resulting in an overall survival rate of nearly 65% [3]. - Among 42 universities, 1967 new companies were formed, with a median of 31 and an average of 47 companies per university [5]. - The top universities for new company formation include Oxford (225), Cambridge (175), Imperial College (132), and Manchester (114) [7]. Group 2: Funding - From 2015 to 2024, 3788 funding events were completed by these universities, with 6 universities exceeding 100 funding events, accounting for 40% of the total [10][11]. - The total funding amount reached £17 billion, with 4 universities raising over £1 billion and 9 universities accounting for 70% of the total funding [14][16]. - The average funding amount per event was approximately £4.5 million, with UCL leading at £9.4 million per event [19]. Group 3: Funding Success Rates - Seven universities achieved a funding success rate exceeding 50%, with Oxford at 79% and Strathclyde at 75% [20][21]. - Among 1337 active companies, 736 are in the seed stage (55%), 402 in venture capital (30%), and 125 in growth stages [23]. Group 4: QS World University Rankings - The 2025 QS World University Rankings for the 42 universities show a median rank of 108 and an average rank of 206, with 16 universities in the top 100 [32]. - There is a positive correlation between university rankings and the number of new companies formed, funding events, and funding amounts [34][36][38]. Group 5: Technology Transfer Centers - Technology transfer centers are crucial for commercializing research, with universities having an average of 72 dedicated staff members in high-performing institutions [42]. - More staff correlates with higher funding events and amounts, although no clear relationship exists between staff numbers and funding success rates [45][52]. Group 6: Incubation and Acceleration - Incubators provide an environment for applying knowledge practically, with notable examples including Imperial College's White City Incubator and Oxford's Startup Incubator [58][59]. - These programs offer tailored support and resources to help startups refine their concepts and scale operations [60][61]. Group 7: Funding Support - Adequate funding is vital for early-stage startups, with Oxford providing nearly 50 types of funding and raising £5 billion [65]. - UKRI has provided over £814 million in funding to university spinouts from 2015 to 2024, enhancing the entrepreneurial landscape [70]. Group 8: Ecosystem Development - Successful commercialization of technology requires a broad network of resources, with universities like Imperial College and Oxford fostering extensive entrepreneurial communities [75][76]. - Collaborative efforts between universities and external organizations enhance the support available to startups, contributing to high survival rates and funding success [78].

Core Insights - The report "Spotlight on Spinouts 2025" reveals that UK universities have established a total of 2064 spinout companies, with a survival rate of approximately 65% [1] Group 1: New Company Formation - A total of 1967 new companies were formed across 42 UK universities, representing about 95% of the total [2] - Four universities have established over 100 new companies, while seven have more than 50 [4] - The top universities by new company formation are: Oxford (225), Cambridge (175), Imperial College (132), and Manchester (114) [5][6] Group 2: Financing - Spinout companies from the 42 universities completed 3788 financing events from 2015 to 2024 [7] - Six universities had over 100 financing events, accounting for 40% of total events [8] - Oxford led with 577 financing events, followed by Cambridge (390) and Bristol (177) [9][10] - The total financing amount reached £17 billion, with four universities exceeding £1 billion in financing [12][15] - Oxford's financing amount was £4.69 billion, Cambridge's was £2.38 billion, and UCL's was £1.63 billion [16] - The average financing amount per event was nearly £4.5 million [19] Group 3: Financing Success Rate - Seven universities had a financing success rate exceeding 50% [21] - Oxford had the highest success rate at 79%, followed by University of Strathclyde (75%) and Cambridge (over 72%) [22][23] Group 4: Financing Rounds and Exits - Among the 1337 active companies, 736 are in the seed stage (55%), 402 in venture capital (30%), and 125 in growth stage [25] - A total of 201 companies achieved successful exits, with 26 IPOs and 175 mergers and acquisitions [27][28] - The top three companies by market capitalization post-IPO are Oxford Nanopore Technologies (£3.3 billion), Exscientia (£2.3 billion), and Darktrace (£1.7 billion) [29] Group 5: QS World University Rankings - The median QS World University ranking for the 42 universities is 108, with an average of 206 [35] - Sixteen universities are in the top 100, with Imperial College (2nd), Oxford (3rd), and Cambridge (5th) leading [36] Group 6: Technology Transfer Centers - Technology transfer centers are crucial for commercializing research, with an average of 72 dedicated staff in universities with over 100 financing events [48] - Cambridge has 150 staff, Oxford has 99, and UCL has 80 [49] Group 7: Incubation and Acceleration - Incubators provide essential environments for applying knowledge practically [64] - Notable programs include Imperial's White City Incubator, Oxford's Startup Incubator, and Cambridge's Deeptech Labs [65][66][67] Group 8: Funding Support - Adequate funding is vital for early-stage startups [68] - Oxford offers nearly 50 types of funding, while Cambridge provides 13 types [69][70] - UKRI has provided over £814 million in funding to university spinouts from 2015 to 2024 [74] Group 9: Ecosystem Development - Successful commercialization requires broad resource mobilization [86] - Universities like Imperial and Oxford have established extensive networks to support startups [87][88] Group 10: Conclusion - The UK aims to enhance its R&D intensity to 2.4% of GDP by 2027, with significant investments planned to support innovation and entrepreneurship [90][91] - Encouraging university professors to engage in entrepreneurship is a key initiative to achieve these goals [92]

导读： 本文欲探讨关税对测序设备、试剂、耗材及服务的影响，分析主要参与者的策略，窥探市场引发的连锁反应，跨国公司正积极寻求对策，本土制造商则有 机会筑建新的长城。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 导 读： 从研发角度，基于成本、技术以及国际合作方面分析，试图探索中美贸易摩擦持续升级下测序行业的机遇。 最近中美贸易摩擦持续升级，双方都对彼此的商品实施大幅度的关税增长，这些举措给我们测序行业带来了显著干扰和不确定，高额的关税阻 碍了设备、试剂以及耗材的进出口贸易，增加了研发和运营开销。 但往往不确定中就蕴含着机会，毕竟《孙子兵法·形篇》里面开篇就说"昔之 善战者，先为不可胜，以待敌之可胜"，意思是会打仗的人都先保证自己不败，然后等待敌人犯错。 当下大环境骤变，竞争格局即将重塑。本 文欲探讨关税对测序设备、试剂、耗材及服务的影响，分析主要参与者的策略，窥探市场引发的连锁反应，跨国公司正积极寻求对策，本土制 造商则有机会筑建新的长城。 放眼全球，测序是一个充满活力的市场，目前该行业主要由NGS驱动，这些技术使大规模基因组分析 ...